Investing Investment Analysts

Nike Falls After Big Earnings Miss

Sam Poser, analyst at Sterne Agee, weighs in why he downgraded Nike stock to "neutral" from "buy."

One Hour Into Trading...

Alan Knuckman, OneStopOption.com, shares his view of the markets.

ACA Impact on Election & Markets

CNBC's Jon Fortt reports on the details of Research In Motion; and Ed Mills, Financial Policy analyst, shares his opinions on the health-care ruling.

Research In Motion Plunges 17%

Nike plunges post-earnings, with the FMHR traders; and discussing whether Research In Motion can recover, with Shaw Wu, Sterne Agee analyst.

Arena Surges on FDA Approval

Shares of Arena Pharmaceuticals spiked on news the FDA approved its anti-obesity drug, with the Fast Money traders; and discussing how tomorrow's ruling on the health care reform could impact the biotech sector, with Mark Schoenebaum, ISI.

Biotech & Drug Stocks: Scotus Ruling Impact

The biotech sector is up more than 1 percent today, and discussing what investors can expect after tomorrow's health care reform ruling, with ISI's biotech and pharmaceuticals major analyst Mark Schoenebaum. "If tomorrow the whole bill is struck down, technically, earnings and revenue estimates for all of biotech and all of pharma companies are going to go up," says Schoenebaum.

Auto Parts Party Over?

Auto parts suppliers are hitting multi-month lows in spite of a new report that says the average age of a car in the U.S. is 11-years-old. CNBC's Phil LeBeau reports. Michael Lasser, UBS equity research analyst, weighs in.

Gartman: Copper & the Economy

Dennis Gartman, The Gartman Letter, says it's interesting that copper is not rallying today even as equities are doing so.

Facebook Face-Off

Gene Munster, Piper Jaffray analyst, says that Facebook will be able to monetize mobile users in 1-3 years, but Brian Wieser, Pivotal Research Group analyst has a "hold" on the stock. Meanwhile Lennar says it sees improvements in pricing and volumes in most markets.

What's Next for Google?

A preview of what to expect from Google's annual software conference today, including whether the tech giant will unveil a new tablet, with Ken Sena, Evercore Partners tech analyst.

Time to 'Friend' Facebook?

Wall Street's coverage of Facebook began with a mixed bag of ratings today. Jason Helfstein, Oppenheimer & Co. senior analyst, explains why he has an "outperform" rating and a price target of $41 dollars on the stock.

Zynga: Game On!

CNBC's Julia Boorstin provides a preview of what to expect when Zynga "unleashes" its new games, and whether that will be enough to boost its battered stock, with Neil Doshi, Citi interactive entertainment analyst.

News Corp. Confirms Considering Split

CNBC's Kayla Tausche reports News Corporation is considering separating its publishing arm from its much larger entertainment division. What does it mean for stockholders? Barton Crockett, Lazard Capital Markets senior analyst, weighs in.

The unresolved euro zone crisis, slowing growth prospects and currency depreciations have created a risk-off environment that makes investors think twice about emerging markets, Pablo Goldberg, Global Head of Emerging Markets Research at HSBC told CNBC’s “Squawk Box Europe”.

Will Obamacare be Overturned?

The Supreme Court is expected to hand down its decision on President Obama's health care law this week, with CNBC's Bertha Coombs. Dave Shove, BMO Capital Markets, and Alex Morozov, Morningstar, weigh in.

Trouble at the High End?

Shares of Tiffany hit their lowest level since October, 2010, with the FMHR traders. Meanwhile Colin Sebastian, RW Baird, says that Zynga is not just a Facebook game -- instead -- expect a broader and more diverse game slate from Zynga. And Toni Sacconaghi, analyst at Sanford Bernstein, discusses whether Microsoft's "Surface" is Apple's biggest threat.

Obamacare Decision: Pharma Winners & Losers

Barbara Ryan, Deutsche Bank Securities analyst, and Catherine Arnold, Credit Suisse analyst, discuss which companies are poised to profit and which are set to lose from the pending Supreme Court decision on health care reform.

(EFA) Seeing Strong Call Demand

(EFA) is the ETF that tracks global stocks including Europe, with the FMHR traders. And Marc Chandler, Brown Brothers Harriman, explains whether the euro will continue to fall.


Fidelity's John Carlson says there's still plenty of opportunity to diversify with emerging market debt, for which the China slowdown is less of a drag.

Expedia Up 65% YTD, Analysts Face Off

An analyst at Piper Jaffray downgraded Expedia to "neutral," but Stifel Nicolaus reiterated its "buy" rating and raised its price target. Mad Money host Jim Cramer, shares his take on the stock.

Summer is here, and along with high temperatures, shorts and flip-flops, another seasonal phenomenon is taking place — college students are graduating, and they’re taking their newly minted degrees into the real world in the hopes of landing a job. But what are their chances of finding work in their fields, or even finding jobs that don’t require them to ask if you want fries with that?Job seekers between ages 16 to 24 who are not enrolled in school and have attained a bachelor’s degree or highe

Recent graduates with arts degrees face a jobless rate of 11.1 percent. With numbers like that, the degree probably seems useless. But many people have gone on to great success after earning “useless” degrees.


Matthew McLennan, manager of the First Eagle Global Fund, focuses on investment options including equities that offer real returns over time. Holdings include gold and big tech names.

Biology Behind Risk-Taking?

John Coates, University of Cambridge research fellow, discusses the evolution of traders and investors over the last few years, and whether traders are becoming more fearful and less daring.


Don Yacktman of Yacktman Asset Management says consumer staples may be plain vanilla, but you know what you're buying and what the companies will be selling in the years to come.

Don Yacktman's Top Stock Picks

Don Yacktman, Yacktman Focused Fund, says he sees big drops in the market as buying opportunities. "We like stocks that are profitable and dull," he tells CNBC's Tyler Mathisen.

Analyst Downgrades Under Armour 'Mostly On Valuation'

UBS analyst Michael Binetti explains his downgrade of Under Armour.

Chesapeake's C-Suite Shuffle

A look at how to play the shakeup at Chesapeake's board, with Tim Rezvan, Sterne Agee analyst.

Bed, Bath & Beyond Q2 View Weak

Shares of the home retailer fell this morning, despite a first quarter earnings beat. Brian Nagel,Oppenheimer senior analyst and Laura Champine, Canaccord Genuity Securiites analyst, weigh in on the outlook for the company.


Bob Brown, Fidelity's bond group president, says with rates unlikely to rise anytime soon and US growth weak, the safe-have, flight-to-quality argument remains sound — even if your're tired of hearing it.

Travelers Emotionally Bonded to Mobile Devices: Survey

A new survey by Intel says half of U.S. travelers feel anxious without their mobile devices. Mike Fard, Intel marketing strategist, and Brian Blair, Wedge Partners senior research analyst, discuss

Procter & Gamble Signals Weakness Ahead

Procter & Gamble has lowered its Q4 earnings and revenue forecasts, with the Fast Money traders.